Research Advances in Animal Experimental Models of Pulmonary Hypertension

doi:10.12300/j.issn.1674-5817.2025-047

Abstract

Abstract:

Pulmonary hypertension (PH), marked by sustained elevation of pulmonary artery pressure, imposes a heavy burden on the right ventricle and may culminate in right heart failure. Its pathogenesis is multifaceted, encompassing endothelial dysfunction, vascular smooth muscle proliferation, inflammation, thrombosis, and genetic factors. Animal models are indispensable for exploring PH mechanisms and therapies, each with unique strengths and limitations. The single - dose monocrotaline (MCT) model offers simplicity and cost - effectiveness, rapidly inducing PH, yet its pathophysiology differs from human idiopathic PH. In contrast, the Sug en5416 combined with chronic hypoxia model better mimics PH progression by inducing pulmonary vasoconstriction and remodeling under low - oxygen conditions, though it requires a longer modelling time and precise hypoxia control. Beyond these, novel techniques like gene - editing engineering enable precise investigation of specific gene functions in PH. Additionally, induced pluripotent stem cell - based 3D organoid technology allows for individualized modelling while preserving patient genetic information for precise clinical translation. This paper comprehensively describes various PH animal models, analyzing their characteristics, applications, and limitations, to provide crucial insights into PH and support the development of new therapeutic strategies and drugs.

Key words: Pulmonary hypertension, Animal model, Monocrotaline, Sugen5416, Organoid

CLC Number:

Q95-33

CHEN Ziyi,SUN Hongyan,KANG Pinfang,et al. Research Advances in Animal Experimental Models of Pulmonary Hypertension[J]. Laboratory Animal and Comparative Medicine. DOI: 10.12300/j.issn.1674-5817.2025-047.

References 81

[1]	MOCUMBI A, HUMBERT M, SAXENA A, et al. Pulmonary hypertension [J]. Nat Rev Dis Primers, 2024, 10(1): 1.
[2]	BOUCHERAT O, AGRAWAL V, LAWRIE A, et al. The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure [J]. Circulation research, 2022, 130(9): 1466-1486.
[3]	QIU F, MIAO H R, HUI H L, et al. MHCII(hi)LYVE1(lo)CCR2(hi) Interstitial Macrophages Promote Medial Fibrosis in Pulmonary Arterioles and Contribute to Pulmonary Hypertension [J]. Circ Res, 2025.
[4]	ZHAO Y, DING C, SU H, et al. Single Test-Based Diagnosis and Subtyping of Pulmonary Hypertension Caused by Fibrosing Mediastinitis Using Plasma Metabolic Analysis [J]. Adv Sci (Weinh), 2025, 12(17): e2416454.
[5]	RIVERA-LEBRON B N, CRUZ MOREL K J, RISBANO M G. Postural changes from ventilatory gas exchange in pulmonary hypertension: Is it a practical solution to a complex question? [J]. Respirology (Carlton, Vic), 2020, 25(4): 354-355.
[6]	CHANG M C J, GRIEDER F B. The continued importance of animals in biomedical research [J]. Lab Anim (NY), 2024, 53(11): 295-297.
[7]	CARMAN B L, PREDESCU D N, MACHADO R, et al. Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension [J]. Am J Pathol, 2019, 189(6): 1133-1144.
[8]	LUO A, HAO R, ZHOU X, et al. Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats [J]. Sci Rep, 2024, 14(1): 14056.
[9]	SUN X Q, KLOUDA T, BARNASCONI S, et al. Pneumonectomy combined with SU5416 or monocrotaline pyrrole does not cause severe pulmonary hypertension in mice [J]. Am J Physiol Lung Cell Mol Physiol, 2024, 327(2): L250-l257.
[10]	UKITA R, STOKES J W, WU W K, et al. A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep [J]. J Vis Exp, 2021, (173).
[11]	WU X H, MA J L, DING D, et al. Experimental animal models of pulmonary hypertension: Development and challenges [J]. Animal Model Exp Med, 2022, 5(3): 207-216.
[12]	ZIMMER A, TEIXEIRA R B, CONSTANTIN R L, et al. The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity [J]. European journal of pharmacology, 2021, 891: 173699.
[13]	SUN J, LIN J, YIN D, et al. Androgen receptor inhibitor ameliorates pulmonary arterial hypertension by enhancing the apoptosis level through suppressing the Notch3/Hes5 pathway [J]. Front Pharmacol, 2025, 16: 1572489.
[14]	MORALES-CANO D, IZQUIERDO-GARCíA J L, BARREIRA B, et al. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model [J]. Frontiers in pharmacology, 2023, 14: 1021535.
[15]	CAI Z, LI J, ZHUANG Q, et al. MiR-125a-5p ameliorates monocrotaline-induced pulmonary arterial hypertension by targeting the TGF-β1 and IL-6/STAT3 signaling pathways [J]. Experimental & molecular medicine, 2018, 50(4): 1-11.
[16]	俞佳慧, 巩倩, 庄乐南. 肺动脉高压动物模型及其在药物研究中的应用进展 [J]. 实验动物与比较医学, 2023, 43(04): 381-397.
	Yu Jiahui, Gong Qian, Zhuang Lenan. Advances in animal models of pulmonary hypertension and their application in drug research [J]. Laboratory Animal and Comparative Medicine, 2023, 43(04): 381-397.
[17]	JIANG H, DING D, HE Y, et al. Xbp1s-Ddit3 promotes MCT-induced pulmonary hypertension [J]. Clinical science (London, England : 1979), 2021, 135(21): 2467-2481.
[18]	谢锦程, 肖梦媛, 邓少东, et al. 肺动脉高压实验模型的研究进展 [J]. 中国比较医学杂志, 2023, 33(09): 79-89.
	Xie Jincheng, Xiao Mengyuan, Deng Shaodong, et al. Research progress on experimental models of pulmonary hypertension [J]. Chinese Journal of Comparative Medicine, 2023, 33(09): 79-89.
[19]	THOMPSON A A R, LAWRIE A. Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension [J]. Trends in molecular medicine, 2017, 23(1): 31-45.
[20]	LONGEVITY O. Retracted: S-Nitroso-L-Cysteine Ameliorated Pulmonary Hypertension in the MCT-Induced Rats through Anti-ROS and Anti-Inflammatory Pathways [J]. Oxid Med Cell Longev, 2023, 2023: 9781259.
[21]	CHEN X, YU X, LIAN G, et al. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension [J]. Biomed Pharmacother, 2024, 174: 116505.
[22]	FLORES C V, CHAN S Y. Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape [J]. Expert Opin Ther Targets, 2025.
[23]	GAO G, CHEN A, YAN Y, et al. Role of insulin signaling dysregulation in pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension [J]. Front Cardiovasc Med, 2025, 12: 1543319.
[24]	HONG J, ARNESON D, UMAR S, et al. Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning [J]. American journal of respiratory and critical care medicine, 2021, 203(8): 1006-1022.
[25]	CAHYONO A, IRWANTO, RAHMAN M A, et al. Progression of pulmonary arterial hypertension: A study in model [J]. Open Vet J, 2024, 14(12): 3498-3504.
[26]	WANG F, XIAO W, LI J, et al. p16(INK4a) promoted progress of MCT induced pulmonary hypertension via maintaining redox balance and autophagy pathway [J]. Biochem Biophys Res Commun, 2025, 749: 151385.
[27]	TATSUOKA Y, HE Z, LIN H M, et al. The role of right ventricular systolic pressure and ARISCAT score in perioperative pulmonary risk assessment [J]. Braz J Anesthesiol, 2025: 844597.
[28]	YI S, QU T, WU H, et al. Knockdown of PLOD2 inhibits pulmonary artery smooth muscle cell glycolysis under chronic intermittent hypoxia via PI3K/AKT signal [J]. Exp Cell Res, 2025, 446(1): 114453.
[29]	TASCA S, TüRCK P, DROSDOWSKI D, et al. Melatonin improves adverse vascular remodelling and redox homeostasis in monocrotaline-induced pulmonary arterial hypertension [J]. Arch Physiol Biochem, 2025: 1-12.
[30]	FU G, QIU L, WANG J, et al. Genome-wide characterization of circular RNAs in three rat models of pulmonary hypertension reveals distinct pathological patterns [J]. BMC Genomics, 2025, 26(1): 127.
[31]	ZHENG R, XU T, LIN Y, et al. Are endothelial cell proliferation and mesenchymal transition as distinguishing characteristics of 3-week Sugen5416/hypoxia mice model? [J]. Cardiovasc Res, 2023, 119(8): e140-e141.
[32]	ISHIBASHI T, INAGAKI T, OKAZAWA M, et al. IL-6/gp130 signaling in CD4(+) T cells drives the pathogenesis of pulmonary hypertension [J]. Proc Natl Acad Sci U S A, 2024, 121(16): e2315123121.
[33]	CHEN C N, HAJJI N, YEH F C, et al. Restoration of Foxp3(+) Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology [J]. American journal of respiratory and critical care medicine, 2023, 208(8): 879-895.
[34]	李新雨, 任周新, 赵鹏. 基于肺动脉高压的肺血管丛状病变的鼠类模型的研究进展 [J]. 中国比较医学杂志: 1-13.
	Li Xinyu, Ren Zhouxin, Zhao Peng. Research progress on rodent models of plexogenic pulmonary arteriopathy based on pulmonary hypertension [J]. Chinese Journal of Comparative Medicine: 1-13.
[35]	DAI J, CHEN H, FANG J, et al. Vascular Remodeling: The Multicellular Mechanisms of Pulmonary Hypertension [J]. Int J Mol Sci, 2025, 26(9).
[36]	BENZA R L, GRüNIG E, SANDNER P, et al. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase [J]. Eur Respir Rev, 2024, 33(171).
[37]	SUMI M P, TUPTA B, SONG K, et al. Expression of soluble guanylate cyclase (sGC) and its ability to form a functional heterodimer are crucial for reviving the NO-sGC signaling in PAH [J]. Free Radic Biol Med, 2024, 225: 846-855.
[38]	BIKOU O, SASSI Y. The Sugen/Hypoxia Rat Model for Pulmonary Hypertension and Right Heart Failure [J]. Methods in molecular biology (Clifton, NJ), 2024, 2803: 163-172.
[39]	HALL I F, KISHTA F, XU Y, et al. Endothelial to mesenchymal transition: at the axis of cardiovascular health and disease [J]. Cardiovasc Res, 2024, 120(3): 223-236.
[40]	MA X, LIU Y, LEI L, et al. Smooth Muscle Cell-Specific LKB1 Protects Against Sugen5416/Hypoxia-Induced Pulmonary Hypertension through Inhibition of BMP4 [J]. American journal of respiratory cell and molecular biology, 2024.
[41]	VISWANATHAN G, KIRSHNER H F, NAZO N, et al. Single-Cell Analysis Reveals Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension [J]. American journal of respiratory and critical care medicine, 2023, 207(10): 1358-1375.
[42]	KARPOV A A, VAULINA D D, SMIRNOV S S, et al. Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension [J]. Heliyon, 2022, 8(3): e09014.
[43]	LIU W, ZHANG Y, LU L, et al. Expression and Correlation of Hypoxia-Inducible Factor-1α (HIF-1α) with Pulmonary Artery Remodeling and Right Ventricular Hypertrophy in Experimental Pulmonary Embolism [J]. Med Sci Monit, 2017, 23: 2083-2088.
[44]	NETO-NEVES E M, BROWN M B, ZARETSKAIA M V, et al. Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition [J]. Am J Pathol, 2017, 187(4): 700-712.
[45]	SINGH S, HOUNG A, REED G L. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation [J]. Circulation, 2017, 135(11): 1011-1020.
[46]	CHEN L, CHEN X, HUANG Y, et al. Establishment of mouse models for severe pulmonary hypertension through 'double-hit' strategies [J]. Exp Physiol, 2024, 109(12): 2026-2030.
[47]	TEERAPUNCHAROEN K, BAG R. Chronic Thromboembolic Pulmonary Hypertension [J]. Lung, 2022, 200(3): 283-299.
[48]	杨振文, 王宙明, 李晟, et al. 慢性血栓栓塞性肺动脉高压的治疗进展 [J]. 中国心血管杂志, 2024, 29(03): 278-282.
	Yang Zhenwen, Wang Zouming, Li Sheng, et al. Advances in the treatment of chronic thromboembolic pulmonary hypertension [J]. Chinese Journal of Cardiovascular Medicine, 2024, 29(03): 278-282.
[49]	AHN C M, HIROMI M. Chronic Thromboembolic Pulmonary Hypertension: Endovascular Treatment [J]. Korean Circ J, 2019, 49(3): 214-222.
[50]	MAHMUD E, MADANI M M, KIM N H, et al. Chronic Thromboembolic Pulmonary Hypertension: Evolving Therapeutic Approaches for Operable and Inoperable Disease [J]. Journal of the American College of Cardiology, 2018, 71(21): 2468-2486.
[51]	GHOFRANI H A, KIM N H. Medical and interventional therapies for inoperable CTEPH: a necessary combination? [J]. Lancet Respir Med, 2022, 10(10): 926-927.
[52]	MANDRAS S A, MEHTA H S, VAIDYA A. Pulmonary Hypertension: A Brief Guide for Clinicians [J]. Mayo Clin Proc, 2020, 95(9): 1978-1988.
[53]	PRICE L C, MARTINEZ G, BRAME A, et al. Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement [J]. Br J Anaesth, 2021, 126(4): 774-790.
[54]	GRADY R M, CANTER M W, WAN F, et al. Pulmonary-to-Systemic Arterial Shunt to Treat Children With Severe Pulmonary Hypertension [J]. Journal of the American College of Cardiology, 2021, 78(5): 468-477.
[55]	MYERS J W, GHANAYEM N S, CAO Y, et al. Outcomes of systemic to pulmonary artery shunts in patients weighing less than 3 kg: analysis of shunt type, size, and surgical approach [J]. J Thorac Cardiovasc Surg, 2014, 147(2): 672-677.
[56]	MENG L, YUAN W, CHI H, et al. Genetic deletion of CMG2 exacerbates systemic-to-pulmonary shunt-induced pulmonary arterial hypertension [J]. Faseb j, 2021, 35(4): e21421.
[57]	SENGSIM J, VIJARNSORN C, CHANTHONG P, et al. Survival comparison in adults with congenital systemic to pulmonary shunt and borderline elevated pulmonary vascular resistance versus Eisenmenger syndrome [J]. Scientific Reports, 2024, 14(1): 29891.
[58]	SAVALE L, BENAZZO A, CORRIS P, et al. Transplantation, bridging, and support technologies in pulmonary hypertension [J]. Eur Respir J, 2024, 64(4).
[59]	XIONG M, YAO J P, WU Z K, et al. Fibrosis of pulmonary vascular remodeling in carotid artery-jugular vein shunt pulmonary artery hypertension model of rats [J]. Eur J Cardiothorac Surg, 2012, 41(1): 162-166.
[60]	LATUS H, KARANATSIOS G, BASAN U, et al. Clinical and prognostic value of endothelin-1 and big endothelin-1 expression in children with pulmonary hypertension [J]. Heart, 2016, 102(13): 1052-1058.
[61]	LINDER A N, HSIA J, KRISHNAN S V, et al. Management of systemic to pulmonary shunts and elevated pulmonary vascular resistance [J]. ERJ Open Res, 2023, 9(6).
[62]	ZHANG J, GU X, CHENG T L, et al. ASH2L Deficiency in Smooth Muscle Drives Pulmonary Vascular Remodeling [J]. Circulation research, 2025.
[63]	LI M, CHEN D, FAN J, et al. The efficacy, safety and clinical feasibility of a percutaneous atrial septal shunt device for pulmonary arterial hypertension: a single-center cohort study [J]. Respiratory research, 2025, 26(1): 67.
[64]	MITCHELL S, GOMEZ R, MATHAVAN A, et al. Development of New Intrapulmonary Shunts in Pulmonary Arterial Hypertension Treated with Sotatercept [J]. Am J Respir Crit Care Med, 2025.
[65]	UDDIN F, RUDIN C M, SEN T. CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future [J]. Front Oncol, 2020, 10: 1387.
[66]	SEKAR D, LAKSHMANAN G, M B. Implications of CRISPR/Cas9 system in Hypertension and its related diseases [J]. J Hum Hypertens, 2021, 35(7): 642-644.
[67]	BISSERIER M, MATHIYALAGAN P, ZHANG S, et al. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension [J]. Circulation, 2021, 144(1): 52-73.
[68]	WANG L, MOONEN J R, CAO A, et al. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension [J]. Circulation research, 2023, 132(5): 545-564.
[69]	刘赛利, 艾可龙, 胡长平. 一氧化氮与肺动脉高压及基于一氧化氮信号通路的肺动脉高压治疗药物研究进展 [J]. 中国药理学与毒理学杂志, 2023, 37(10): 792-797.
	Liu Sali, Ai Kelong, Hu Changping. Nitric oxide and pulmonary hypertension: Advances in research on therapeutic drugs targeting the nitric oxide signaling pathway [J]. Chinese Pharmacological and Toxicological Bulletin, 2023, 37(10): 792-797.
[70]	DOGGRELL S A. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)? [J]. Expert Opin Biol Ther, 2023, 23(7): 589-593.
[71]	EDDAHIBI S, MORRELL N, D'ORTHO M P, et al. Pathobiology of pulmonary arterial hypertension [J]. The European respiratory journal, 2002, 20(6): 1559-1572.
[72]	DEVENDRAN A, KAR S, BAILEY R, et al. The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling [J]. Cells, 2022, 11(23).
[73]	WANG T, DUAN Y, LIU D, et al. The effect of transglutaminase-2 inhibitor on pulmonary vascular remodeling in rats with pulmonary arterial hypertension [J]. Clin Exp Hypertens, 2022, 44(2): 167-174.
[74]	韩新源, 王顺达, 雍志军, et al. 5-羟色胺通过5-羟色胺2A受体对肺动脉成纤维细胞的激活作用 [J]. 山西医科大学学报, 2021, 52(12): 1558-1562.
	Han Xinyuan, Wang Shunda, Yong Zhijun, et al. Activation of pulmonary artery fibroblasts by serotonin via the serotonin 2A receptor [J]. Journal of Shanxi Medical University, 2021, 52(12): 1558-1562.
[75]	FUJIWARA M, YAGI H, MATSUOKA R, et al. [Analysis of genetic mutation and modifier genes in pulmonary arterial hypertension] [J]. Nihon Rinsho, 2008, 66(11): 2071-2075.
[76]	JIAO Y R, WANG W, LEI P C, et al. 5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis [J]. Gene, 2019, 680: 34-42.
[77]	ZHOU K, ZHAO Z, LI S, et al. A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression [J]. Sci Rep, 2020, 10(1): 18420.
[78]	LIU C, YUAN B, CHEN H, et al. Effects of MiR-375-BMPR2 as a Key Factor Downstream of BMP15/GDF9 on the Smad1/5/8 and Smad2/3 Signaling Pathways [J]. Cell Physiol Biochem, 2018, 46(1): 213-225.
[79]	POPP S, SCHMITT-BöHRER A, LANGER S, et al. 5-HTT Deficiency in Male Mice Affects Healing and Behavior after Myocardial Infarction [J]. J Clin Med, 2021, 10(14).
[80]	CHEN Y, MA P, BO L, et al. Isorhamnetin alleviates symptoms and inhibits oxidative stress levels in rats with pulmonary arterial hypertension [J]. Iran J Basic Med Sci, 2024, 27(12): 1616-1623.
[81]	ZHANG J, JIA Z, PAN H, et al. From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapies [J]. Transl Cancer Res, 2025, 14(4): 2495-2507.